Global consumption patterns of combination hypertension medication: an analysis of pharmaceutical sales data from 2010–2021

Jayawardana, Sahan ORCID: 0000-0001-7081-3910, Campbell, Allen, Aitken, Murray, Andersson, Charlotte E., Mehra, Mandeep R. and Mossialos, Elias ORCID: 0000-0001-8664-9297 (2024) Global consumption patterns of combination hypertension medication: an analysis of pharmaceutical sales data from 2010–2021. PLOS Global Public Health, 4 (9). ISSN 2767-3375

Text (journal.pgph.0003698) - Published Version Available under License Creative Commons Attribution. Download (1MB)

• Scopus publication

Abstract

Hypertension is the most significant risk factor for cardiovascular disease and mortality worldwide, affecting 1.3 billion adults. Global disparities in hypertension control are widening with low- and middle-income countries (LMIC) having the fastest growing rates of hypertension and low rates of control. Treatment for hypertension can be challenging, with multiple drug classes and dosing schedules. Combination antihypertensives have been suggested as a solution for their efficacy and potential to improve adherence. Global consumption of combination and non-combination antihypertensives across 75 countries and 2 regions from 2010 to 2021 was estimated using the IQVIA MIDAS database on pharmaceutical sales. Consumption rates were standardized using Standard Units (SUs) and analysed by high-income (HIC), upper-middle income (UMIC), and LMIC income classification. Global median consumption rate of all antihypertensives per 1000 inhabitants per day increased from 184.78 SUs in 2010 to 325.6 SUs in 2021, with HICs consistently having the highest rates. Median consumption rates of combination and non-combination antihypertensives increased across all country income groups but combination drugs were consumed at a lower rate and proportion. LMICs consumed a higher percentage of combination antihypertensives relative to non-combination (45.5%) than UMICs (24.3%) and HICs (24.4%) in 2021. While combination antihypertensives may be preferred for their potential for increased adherence and effectiveness, their global uptake is inconsistent. HICs consume less combination medication relative to non-combination, despite higher overall consumption rates of antihypertensives. LMICs show increasing use of combination medications, indicating a shift towards their use.

Item Type:	Article
Additional Information:	© 2024 The Authors
Divisions:	Health Policy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	23 Sep 2024 10:24
Last Modified:	17 Oct 2024 16:58
URI:	http://eprints.lse.ac.uk/id/eprint/125490

Actions (login required)

View Item